International Stem Cell Reports Second Quarter 2013 Financial Results

Gross margin improved by 600 basis points to 77 percent -Cash burn, excluding capital expenditures and patent costs, for the first six months of 2013 reduced by 16 percent compared to the same period of 2012 -In preparation for the IND-enabling studies and after discussion with the office of Cellular, Tissue and Gene Therapies, ISCO's R&D team ... (more)

http://www.hispanicbusiness.com/2013/8/20/international_stem_cell_reports_second_quarter.htm